SOLID BIOSCIENCES INC (SLDB)
Health Care · Gene therapy biotechnology · NASDAQ
A clinical-stage biotechnology company developing gene therapies to treat rare, life-threatening neuromuscular and cardiac diseases.
What SOLID BIOSCIENCES INC does
Solid Biosciences is a life sciences company focused on developing gene therapies for rare neuromuscular and cardiac diseases. Its pipeline includes candidates for Duchenne muscular dystrophy, Friedreich’s ataxia, and catecholaminergic polymorphic ventricular tachycardia, alongside a platform for discovering enabling gene therapy technologies such as novel delivery capsids.
Themes: gene therapy, rare diseases, neuromuscular diseases, cardiac diseases, Duchenne muscular dystrophy, genetic medicine discovery platform
Fundamentals
- Price$6.82 as of 2026-10-08 close
- Market cap$731M as of 2026-08-04 (share count; price 2026-10-08)
- 1-year return+8.1% 2025-10-08 close $6.31 → 2026-10-08 close $6.82
- P/En/a negative earnings
- Net margin-1062.3% FY2022, SEC XBRL
- ROE-96.8% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Beta1.68 as of 2026-09-02
- Last reported earnings2026-03-06 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How SLDB compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SOLID BIOSCIENCES INC looks technically
SOLID BIOSCIENCES INC (SLDB) is trading 10.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 303 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-06-10, breaking below its recent trading range. It is 40.4% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 10.3% below its 200-day average, the long-term trend line — a long-term downtrend | -10.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.67 | $8.67 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.61 | $7.61 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 23 calendar days ago — the swings before that are what the structure reading is measured on | 23 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 7.65. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 303 trading days ago — a "golden cross", a bullish long-term signal | 303 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with sellers in control | 36.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30) | 31.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($6.63 to $9.03) — its "stochastic" reading is 8 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 7.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $11.45 | $11.45 |
|---|---|---|
| From the 52-week high | it is 40.4% below its 52-week high (its highest price of the past year) | -40.4% |
| Above the 52-week low | it is 79.9% above its 52-week low (its lowest price of the past year) | +80.0% |
| Below the 52-week high | it is 40.4% below its highest point of the past year | 40.4% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-10, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-10, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $822.60 (set on 2018-06-19) | $822.60 |
| Given back of the 52-week move | over the past year its closes ranged ($3.93 to $11.15), and it has given back a bit over half of its rise from last year’s low — 60% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.46 to $6.69. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 60.0% |
| From the all-time high | it is 99.2% below its all-time high | -99.2% |
| Nearest price level | it is sitting right on a support level at $6.79 — a price it turned at three times since 2025-08-13, most recently on 2026-05-05. Since 2024-10-08 it has 11 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $1.81 (set on 2023-10-30) | $1.81 |
| Above the all-time low | it is 276.8% above its all-time low | +276.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 74% of it) | 74th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4438 between its high and its low — about 6.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4438 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.16 and $9.41 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.16 – $7.79 – $9.41 |
| Typical daily range (% of price) | its price moves about 6.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.5% |
| Stretch from the 200-day average | it is trading 1.8 daily ranges below its 200-day average price (10.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.08× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.5% |
|---|---|---|
| Open gap | it gapped 2.4% below the previous close 22 sessions ago and has not traded back through the level it left behind at 10.25 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.4% |
| Gap filled | a 2.3% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -3.4% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 32.4 percentage points (the stock lost 31.3% while the market gained 1.0%) | -32.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 41.8 percentage points (the stock lost 38.0% while the market gained 3.8%) | -41.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 29.3 percentage points (the stock lost 11.9% while the market gained 17.5%) | -29.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 6.9 percentage points (the stock gained 8.1% while the market gained 15.0%) | -6.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 26% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.3% of the share price, which is taken to mean a barrier that gives way easily. | -26.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.80 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | -12.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $8.53 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -20.0% |
Price levels it has turned at before
SLDB last closed at $6.82 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.79 | Support | 0.5% below the last close | turned there three times · 2025-08-13 to 2026-05-05 |
| $6.33 | Support | 7.1% below the last close | turned there five times · 2024-11-06 to 2026-06-09 |
| $7.35 | Resistance | 7.8% above the last close | turned there twice · 2025-07-30 to 2026-02-10 |
| $6.13 | Support | 10.1% below the last close | turned there twice · 2024-11-25 to 2025-12-05 |
| $7.95 | Resistance | 16.5% above the last close | turned there twice · 2026-03-26 to 2026-05-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $7.65.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $7.65 and $8.71 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 11 trading days, since 2026-09-24.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.38 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$18.62 range $11.00 – $26.00; median $18.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SLDB
- Consensus EPS estimate-$0.4144 next reporting period, as of 2026-10-05
- Estimate change, 30 days-$0.00154 from -$0.4129, on 2026-08-31, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant history of operating losses and uncertainty regarding future profitability.","High reliance on the clinical success and regulatory approval of its gene therapy candidates.","Requirement for additional capital to fund research, development, and commercialization activities."]
What changed in the latest 10-Q
AI-assisted comparison of SLDB's 10-Q filed 2026-05-12 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) references audited financial statements for year ended December 31, 2025 and Form 10-K filed March 19, 2026, versus older filing (2025-11-03) which referenced year ended December 31, 2024 and Form 10-K filed March 6, 2025
- Newer filing adds: SGT-003 awarded Orphan Drug designation from European Commission for treatment of Duchenne
- Newer filing adds: mention of expansion to age groups in clinical trial amendment wording
- Newer filing adds: announcement of positive interim data on March 11, 2026 as of February 23, 2026 data cutoff
- Newer filing adds: statement that SGT-003 has been generally well tolerated in 47 participants dosed as of May 11, 2026
- Newer filing adds: reference to low-burden, steroid-only prophylactic immunomodulation profile
- Removed:
- Older filing (2025-11-03) specified amendments to clinical trial protocol occurred in September 2024 and June 2025; newer filing removes specific amendment dates
- Older filing provided detailed interim data: 10 participants with mean microdystrophin expression of 58%, mean microdystrophin positive fibers of 51%, specific biomarker data (CK, ALT, AST, lactate dehydrogenase); newer filing removes these specific data points
- Older filing referenced announcement date of November 3, 2025 with September 29, 2025 data cutoff; newer filing removes this specific prior announcement
- Reworded:
- Older filing: SGT-212 received Fast Track and Rare Pediatric Disease designations; newer filing: SGT-212 received Fast Track, Orphan Drug and Rare Pediatric Disease designations
- Older filing referenced 'pediatric participants'; newer filing uses 'pediatric patients'
- Older filing: 'we amended the INSPIRE DUCHENNE clinical trial protocol' with specific dates; newer filing: 'we amended the clinical trial protocol' without specific dates
- Notes:
- Older filing text appears truncated at end (cuts off mid-word 'lactate dehydroge'), limiting full assessment of removal scope
- Comparison spans different quarterly periods (Q3 2025 vs Q1 2026) and different fiscal year references, so some differences reflect updated reporting periods rather than substantive changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SLDB — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SLDB as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 23,759,714
- Reported value $237,359,539
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SLDB's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SLDB had 17,106,152 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
SLDB had 16.0% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 19.63 days to cover at the same settlement.
- Reported short interest (shares) 17,106,152
- Short interest (% of shares outstanding) 16.0%
- Prior settlement (shares) 16,384,018
- Reported change 4.41%
- Days to cover (reported) 19.63
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sarepta Therapeutics (SRPT)
- PTC Therapeutics (PTCT)
- REGENXBIO (RGNX)
- Voyager Therapeutics (VYGR)
- Rocket Pharmaceuticals (RCKT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SLDB vs…
SOLID BIOSCIENCES INC is found in…
Frequently asked questions
What does SOLID BIOSCIENCES INC (SLDB) do?
Solid Biosciences is a life sciences company focused on developing gene therapies for rare neuromuscular and cardiac diseases. Its pipeline includes candidates for Duchenne muscular dystrophy, Friedreich’s ataxia, and catecholaminergic polymorphic ventricular tachycardia, alongside a platform for discovering enabling gene therapy technologies such as novel delivery capsids.
What sector is SOLID BIOSCIENCES INC (SLDB) in?
SOLID BIOSCIENCES INC (SLDB) is classified in the Health Care sector. Its industry is Gene therapy biotechnology. It trades on NASDAQ.
Who are SOLID BIOSCIENCES INC's (SLDB) competitors?
Notable peers of SOLID BIOSCIENCES INC (SLDB) include Sarepta Therapeutics, PTC Therapeutics, REGENXBIO, Voyager Therapeutics and Rocket Pharmaceuticals. This peer set is informational only — not financial advice.
Is SOLID BIOSCIENCES INC (SLDB) overbought or oversold right now?
SOLID BIOSCIENCES INC (SLDB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 31, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SLDB come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.